Surgical Services, John Hunter Hospital, Newcastle, New South Wales, Australia.
Department of Endocrinology, John Hunter Hospital, Newcastle, New South Wales, Australia.
Endocrinol Diabetes Metab. 2023 Mar;6(2):e398. doi: 10.1002/edm2.398. Epub 2023 Feb 3.
De-escalated treatment of hemithyroidectomy without radioactive iodine (RAI) is now accepted for patients with low-risk, well-differentiated thyroid cancer (WDTC). The benefit of long-term follow-up care remains controversial. This study aims to describe parameters associated with less than total thyroidectomy, and discharge from specialist follow-up in patients with low-risk WDTC in Australia.
An online survey was distributed to Australian members of Endocrine Society of Australia, Australian and New Zealand Endocrine Surgeons, and Australian Society of Otolaryngology, Head and Neck Surgery. Clinicians completed a survey of management and follow-up care preferences for four clinical vignettes (all low-risk WDTC).
119 clinicians (48% endocrinologists, 55% male) answered at least one question. The majority (59%) of respondents recommended less than total thyroidectomy and omission of RAI in patients with WDTC <2 cm. Most (62%) would discharge a patient with micropapillary thyroid cancer within 1 year following total thyroidectomy. In contrast, for WDTC 1-4 cm, >90% of clinicians would continue specialist follow-up for at least 5 years. The majority of clinicians felt that patients experienced disproportionate fear of recurrence and were reassured by follow-up. After multivariable analysis, clinicians who participated in multidisciplinary teams (MDTs) were more likely to choose de-escalated care for both initial treatment (p = .005) and follow-up care (>5 years, p = .05).
Clinician attitudes captured by this survey reflect recent changes in guidelines towards hemithyroidectomy for low-risk WDTC, particularly amongst MDT attendees. There is a need to further examine the impact of de-escalated care on fear of recurrence and quality of life in thyroid cancer survivors.
对于低危、分化良好的甲状腺癌(WDTC)患者,不使用放射性碘(RAI)的甲状腺次全切除术的降级治疗现在已被接受。长期随访护理的益处仍存在争议。本研究旨在描述与澳大利亚低危 WDTC 患者甲状腺次全切除术和专科随访出院相关的参数。
一项在线调查分发给澳大利亚内分泌学会、澳大利亚和新西兰内分泌外科医生以及澳大利亚耳鼻喉科、头颈外科协会的成员。临床医生对四个临床病例(均为低危 WDTC)的管理和随访护理偏好进行了调查。
119 名临床医生(48%为内分泌学家,55%为男性)回答了至少一个问题。大多数(59%)受访者建议对 WDTC<2cm 的患者进行甲状腺次全切除术和不使用 RAI。大多数(62%)将在甲状腺全切除术后 1 年内出院的患有微乳头状甲状腺癌的患者。相比之下,对于 WDTC 1-4cm,超过 90%的临床医生将继续进行至少 5 年的专科随访。大多数临床医生认为患者对复发的恐惧不成比例,并通过随访得到安慰。多变量分析后,参加多学科团队(MDT)的临床医生更有可能选择降级治疗,无论是初始治疗(p=0.005)还是随访治疗(>5 年,p=0.05)。
本调查中捕获的临床医生态度反映了最近对低危 WDTC 患者甲状腺次全切除术指南的变化,特别是在 MDT 参与者中。需要进一步研究降级治疗对甲状腺癌幸存者复发恐惧和生活质量的影响。